Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service BPH procedures cases in West Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 1,352 | 36% |
| 2020 | 12 | 1,039 | 41% |
| 2021 | 13 | 922 | 46% |
| 2022 | 14 | 951 | 50% |
| 2023 | 14 | 670 | 55% |
| 2024 | 11 | 613 | 58% |
| 2025 from claims | – | 461 373–541 | 59% |
| 2026 forecast | – | 451 353–566 | 60% |
| 2027 forecast | – | 442 328–585 | 61% |
| 2028 forecast | – | 434 307–599 | 62% |
| 2029 forecast | – | 425 289–610 | 63% |
| 2030 forecast | – | 417 273–618 | 64% |
TURP, laser enucleation and vaporization, UroLift, Rezum. Professional codes (what the surgeon bills): CPT 52601, 52648, 52649, 52441, 52442, 53854, 55874.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in West Virginia; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 8% inpatient hospital, 92% hospital outpatient. The share outside the hospital has moved −14 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~450 | ~38 | ~410 |
| 2027 · ~440 | ~37 | ~400 |
| 2028 · ~430 | ~36 | ~400 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 187 | 13,311−3.9%/yr | −3.9%/yr | 5.9 | 45% | 13,300 in 20300%/yr |
| Texas | 150 | 9,762−6.5%/yr | −6.5%/yr | 4.5 | 41% | 9,710 in 2030−0.1%/yr |
| Georgia | 60 | 5,270−5.6%/yr | −5.6%/yr | 6.1 | 42% | 4,930 in 2030−1.1%/yr |
| Maryland | 65 | 4,904−8.2%/yr | −8.2%/yr | 5.5 | 82% | 4,770 in 2030−0.5%/yr |
| Tennessee | 62 | 4,487−4.2%/yr | −4.2%/yr | 6.3 | 43% | 4,180 in 2030−1.2%/yr |
| Virginia | 64 | 4,475+1.2%/yr | +1.2%/yr | 4.3 | 32% | 3,890 in 2030−2.3%/yr |
| North Carolina | 53 | 4,163−9.2%/yr | −9.2%/yr | 4.2 | 15% | 3,750 in 2030−1.7%/yr |
| South Carolina | 59 | 3,847−5.5%/yr | −5.5%/yr | 5.6 | 23% | 3,310 in 2030−2.5%/yr |
| Oklahoma | 41 | 2,246−10%/yr | −10%/yr | 4.6 | 36% | 2,140 in 2030−0.8%/yr |
| Mississippi | 29 | 2,122−13%/yr | −13%/yr | 5.6 | 48% | 1,630 in 2030−4.3%/yr |
| Louisiana | 22 | 1,850−5.9%/yr | −5.9%/yr | 4.5 | 30% | 1,540 in 2030−3.1%/yr |
| Arkansas | 29 | 1,636−4.1%/yr | −4.1%/yr | 4.3 | 35% | 1,550 in 2030−0.9%/yr |
| Kentucky | 16 | 1,515−6.7%/yr | −6.7%/yr | 3.3 | 23% | 1,270 in 2030−2.9%/yr |
| Alabama | 14 | 1,324−10%/yr | −10%/yr | 3.0 | 18% | 940 in 2030−5.5%/yr |
| Delaware | 11 | 729−4.8%/yr | −4.8%/yr | 4.2 | 45% | 790 in 2030+1.4%/yr |
| District of Columbia | 6 | 425−0.5%/yr | −0.5%/yr | 6.7 | 58% | 390 in 2030−1.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 21 | 920−7.2%/yr | −7.2%/yr | 4.50.9× | 0% | 990 in 2030+1.3%/yr |
| Hysterectomy, hysteroscopy & ablation | 4 | 616−2.8%/yr | −2.8%/yr | 3.21.2× | 5% | 580 in 2030−1.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 6 | 311−5%/yr | −5%/yr | 1.50.6× | 0% | 360 in 2030+2.4%/yr |
| Prostatectomy & nephrectomy | 1 | 137+2.2%/yr | +2.2%/yr | 0.70.6× | 0% | 260 in 2030+11%/yr |
BPH procedures in every state, and its device makers · Every procedure market in West Virginia · Every state · Compare with Florida
Olympus leads with 84% of company spending on these surgeons in 2025, +84 pts on 2024.
In 2025, 5 companies reported engagement with West Virginia’s surgeons worth $1,665 in consulting, speaking, meals and travel tied to these products, about $151 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.